stockrow
Saturday 7 November 2026
Export KRSA’s income statement to Excel — free account
Korsana Biosciences, Inc.
KRSA Healthcare Biotechnology
- Revenue
- −43.2%
- EPS
- −272.7%
- Free cash flow
- −184.7%
Quarter to June 2026, against a year earlier
30.77
0.34
+1.12%
Follow KRSA
Alert me
Korsana Biosciences, Inc. (KRSA) P/E ratio
Korsana Biosciences, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 3.0× (August 2024) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| Mar 2025 | 0.0× | — |
| 16 more quarters | Free account |
Against its own ten years
Low 0.0×
High 3.0×
Ten-year median
0.0×
Current reading's percentile
97
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| OCUL Ocular Therapeutix, Inc. compare | n/m |
| TSHA Taysha Gene Therapies, Inc. compare | n/m |
| MLYS Mineralys Therapeutics, Inc. compare | n/m |
| KRSA Korsana Biosciences, Inc. | n/m |
| TYRA Tyra Biosciences, Inc. compare | n/m |
| GPCR Structure Therapeutics Inc. Sponsored ADR compare | n/m |
| ANAB AnaptysBio, Inc. compare | n/m |
| DMRA Galecto, Inc. compare | 24.7× |
| AAPG Ascentage Pharma Group International - Unsponsored ADR compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)